Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Rzeszow – page 27

337 clinical trials in Rzeszow, Poland across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Rzeszow at a glance
337
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

337 trials in Rzeszow

Open in trial search

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Breast cancer+2

Not recruiting

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:F. Hoffmann-La Roche AG

Anal fistula+1

Not recruiting

Study on the Effectiveness and Safety of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells for Treating Complex Perianal Fistulas in Children with Crohn's Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study of Risankizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Factor VIII deficiency+3

Not recruiting

Study on the Safety and Effectiveness of SerpinPC for Patients with Severe Hemophilia A or B

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Sponsor:Apcintex Limited

Myelodysplastic syndrome

Not recruiting

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Colitis ulcerative

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Relapsing multiple sclerosis

Not recruiting

Study on the Safety and Efficacy of BIIB091 and Diroximel Fumarate for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Diroximel Fumarate
  • Sponsor:Biogen Idec Research Limited

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Rzeszow

What the registry says about research in the country

01 Inflammatory and Autoimmune Conditions

Ongoing research focusing on innovative treatments for inflammatory bowel diseases and autoimmune conditions, including studies on new therapies for ulcerative colitis and Crohn's disease.

  • Ulcerative Colitis
  • Crohn's Disease
  • Psoriasis
  • Atopic Dermatitis

Multiple trials evaluating novel compounds and biological therapies for inflammatory conditions.

02 Cardiovascular and Metabolic Research

Studies investigating treatments for heart failure prevention and metabolic disorders, with emphasis on innovative therapeutic approaches for obesity and cardiovascular health.

  • Heart Failure Prevention
  • Obesity Management
  • Chronic Kidney Disease

Focus on combination therapies and novel compounds for cardiometabolic conditions.

03 Neurological and Immune System Disorders

Clinical investigations targeting multiple sclerosis and chronic inflammatory conditions affecting the nervous system.

  • Multiple Sclerosis
  • CIDP
  • Immune System Diseases

Evaluation of new therapeutic agents for managing neurological and immune-mediated conditions.

04 Specialized Medical Conditions

Research on various specialized conditions including geographic atrophy and reproductive health treatments.

  • Age-Related Macular Degeneration
  • Contraceptive Studies
  • Pulmonary Conditions

Diverse studies focusing on improving patient outcomes across multiple therapeutic areas.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.